Editor The COVID-19 pandemic has significantly disrupted cancer treatment nationwide, despite NHS England urging Trusts to ensure cancer care continued1. Cautious clinical guidance2 – avoiding anastomoses, reducing laparoscopy and deferring… Click to show full abstract
Editor The COVID-19 pandemic has significantly disrupted cancer treatment nationwide, despite NHS England urging Trusts to ensure cancer care continued1. Cautious clinical guidance2 – avoiding anastomoses, reducing laparoscopy and deferring higher risk patients – coupled with the diversion of resources to manage the expected surge, caused UK cancer surgery numbers to plummet. The major concern was unwittingly performing surgery on COVID positive patients or patients becoming infected post-operatively. Early data from Wuhan suggested a 20 per cent mortality for COVID-19 positive elective surgery patients3. Unnecessarily endangering staff and other patients was also a key concern. Additionally, the potential reduction in ITU capacity and the possibility of litigation were prominent considerations4. In Oxford, we confined COVID-19 positive cases to our acute site, designated the Churchill Hospital the ‘clean’ site and commissioned support from the independent hospital. Since UK lockdown on 23rd March, we have conducted over 400 cancer procedures and extended our services to support more severely affected Trusts. We introduced 14 days preoperative shielding and minimised hospital visits using drive-through phlebotomy and swabbing services. CT chest was used for major procedures until routine pre-operative viral swab testing was available. All theatre staff used level II PPE and underwent robust simulation training. We use enhanced recovery protocols and where possible, early discharge with intensive telephone follow-up. Monitoring of the cohort continues, but to date we have no reported peri-operative COVID-19 infections. During the recovery phase, we must address the needs of patients whose treatment has been put on hold5. Firstly, we need to extend surgery to cancer patients with significant co-morbidities and patients with clinically urgent benign disease. Secondly, we must resume diagnostic services to avoid a peak of deaths due to delayed diagnoses. Teamwork, agile decision making and above all, systematic testing of staff and patients is essential to restore workforce confidence, improve efficiency and resource utilisation.
               
Click one of the above tabs to view related content.